Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Endocrinology
•
Peripheral Vascular Disease
Do you prioritize prescribing semaglutide in patients with type 2 diabetes and peripheral arterial disease, given trial data demonstrating improved maximum walking distance with its use?
Bonaca MP, et al.,
PMID 40169145
Related Questions
Would the diagnostic yield for ABIs or peripheral arterial duplex doppler in a patient with metal rods in both legs be similar or acceptable in comparison to those tests in a patient without metal rods?
Besides treadmill, what other exercises may be considered for post-exercise ABIs, and are their diagnostic parameters identical to standard post-exercise ABIs?
Is it a good practice to prescribe clonidine to take as needed for occasional severe blood pressure elevations?
Do you favor Sotagliflozin over SGLT2i alone for cardiovascular risk reduction in patients with Type 2 diabetes and chronic kidney disease?
Would you prescribe a GLP-1 receptor agonist for an obese patient with low to moderate cardiovascular risk but a high CAC score?
What is the clinical significance of a paradoxical decrease in HDL cholesterol after starting statin therapy?
How do you evaluate the etiology of worsening limb ischemia between progression of known PAD or cardioembolic disease?
Can blood pressure measurements be reliably interpreted and obtained using forearm cuff pressures, especially for patients in certain situations such as obesity?
Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?
Is there any difference in the cardiovascular risk reduction profile of brand name Vascepa versus generic icosapent ethyl for patients with hypertriglyceridemia?
